Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 3Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Carcinoma, Renal Cell 19Sarcoma 4Neuroendocrine Tumors 4Neoplasms 4Carcinoma, Medullary 4Carcinoma, Hepatocellular 4Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Urethral Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Cancer, Papillary 2Small Cell Lung Carcinoma 2Sarcoma, Ewing 2Prostatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Melanoma 2Lung Neoplasms 2Kidney Neoplasms 2Endometrial Neoplasms 2Colorectal Neoplasms 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Neuroendocrine 2Carcinoma 2Adenocarcinoma, Follicular 2Wilms Tumor 1Urologic Neoplasms 1

Interventions

cabozantinib 2pembrolizumab 1lenvatinib 1fludarabine 1Selenomethionine 1Nivolumab 1Ipilimumab 1Everolimus 1Cyclophosphamide 1CTLA-4 Antigen 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Clear-cell metastatic renal cell carcinoma × cabozantinib × Clear all
NCT05012371 2026-03-05

Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
90 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

NCT05122546 2026-03-05

CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer

City of Hope Medical Center

Phase 1 Active not recruiting
31 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡